- Home
- MCHX vs TLSA Comparison
MCHX vs TLSA Comparison
Compare MCHX & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCHX | TLSA |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 182.7M |
| IPO Year | 2004 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MCHX | TLSA |
|---|---|---|
| Price | $1.66 | $1.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.2K | ★ 453.8K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $46,494,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.26 | $0.63 |
| 52 Week High | $2.31 | $2.60 |
Technical Indicators
Market Signals| Indicator | MCHX | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 50.26 | 42.23 |
| Support Level | $1.60 | $1.45 |
| Resistance Level | $1.75 | $1.62 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 40.03 | 44.23 |
Price Performance
Historical ComparisonAbout MCHX Marchex Inc. Class B
Marchex Inc harnesses the power of AI and conversational intelligence to provide actionable insights aligned with prescriptive vertical market data analytics, driving operational excellence and revenue acceleration. Marchex enables executive, sales, and marketing teams to optimize customer journey experiences across communications channels, enabling enterprise strategies, empowering businesses to increase revenue through informed decision-making and strategic execution.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.